Case Review Form

      * Denotes required field.


      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address




      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

J&J Settles Risperdal Lawsuit

Filed February 14th, 2013 admin

Johnson & Johnson (J&J) reached a settlement on the first day of a trial of a lawsuit brought over claims its antipsychotic drug, Risperdal, caused a male plaintiff to grow breast tissue.

The lawsuit filed by Aron Banks, 21, was the first to go to trial on claims that Risperdal caused boys to grow breasts. A second trial on the same claim is set to begin September 20 in Philadelphia, said. There are currently 420 lawsuits pending against J&J and its Janssen unit that allege personal injuries caused by Risperdal. About 130 of the lawsuits involve allegations that the drug caused young males to grow breasts, said. Banks claimed he endured psychological trauma from breast growth he experienced while taking the drug as a child from 2000 to 2004.

U.S. regulators have been investigating the sales practices of Risperdal since 2004 and J&J has been accused of marketing the drug for unapproved uses, said. The terms of this case’s settlement were not released.

This is not the first time J&J has had to go to court over Risperdal. In April, a judge ordered J&J to pay $1.2 billion in fines over Risperdal marketing. That ruling came just three months after J&J settled a trial in Texas over its sales practices for $158 million, said. That case included claims that the company marketed the drug for children while lacking approval by regulators for such use. In June 2011, a judge in South Carolina ordered the company to pay $327 million in penalties for deceptively marketing the medicine.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!